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Introduction: Pay-for-performance programs and economic constraints call for solutions to improve the quality
of health care without increasing costs. Many studies have shown decreased morbidity in major surgery when
perioperative goal directed fluid therapy (GDFT) is used. We assessed the clinical and economic burden of postsurgical
complications in the University HealthSystem Consortium (UHC) in order to predict potential savings with GDFT.
Methods: Data from adults who had a major surgical procedure in 2011 were screened in the UHC database. Thirteen
post-surgical complications were tabulated. In-hospital mortality, hospital length of stay and costs from patients with and
without complications were compared. The risk ratios reported by the most recent meta-analysis were used to estimate
the potential reduction in post-surgical morbidity with GDFT. Potential cost-savings were calculated from the actual and
anticipated morbidity rates.
Results: A total of 75,140 patients met the search criteria, and 8,421 patients developed one or more post-surgical
complications (morbidity rate 11.2%). In patients with and without complications, in-hospital mortality was 12.4% and
1.4% (P <0.001), mean hospital length of stay was 20.5 ± 20.1 days and 8.1 ± 7.1 days (P <0.001) and mean direct costs
were $47,284 ± 49,170 and $17,408 ± 15,612 (P <0.001), respectively. With GDFT, morbidity rate was projected to decrease
to 8.0 - 9.3%, yielding gross costs savings of $43 M - $73 M for the study population or $569 - $970 per patient.
Conclusion: Postsurgical complications have a dramatic impact (+172%) on costs. Potential costs savings resulting from
GDFT are substantial. Perioperative GDFT may be recommended not only to improve quality of care but also to
decrease costs.Introduction
Pay-for-performance programs and economic constraints
call for solutions improving the quality of health care
without increasing costs [1]. In this respect, the American
Society of Anesthesiology is developing a perioperative
surgical home program in order to optimize quality and
continuity of care for surgical patients [2,3]. Perioperative
goal directed fluid therapy (GDFT) is a general term refer-
ring to targeted hemodynamic and fluid management
using parameters such as stroke volume, cardiac output,
and/or oxygen delivery, in conjunction with standard vital
signs in managing patients during and immediately after
surgery. Many studies have shown decreased morbidity in* Correspondence: frederic_michard@edwards.com
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unless otherwise stated.major surgery when GDFT is used [4,5] and it is now
recommended by the National Health Service in the
UK [6], by the French Society of Anesthesiology [7],
and by the Enhanced Recovery After Surgery (ERAS)
society in Europe [8]. Despite this, adoption of GDFT
in the United States is poor [9,10]. Perioperative GDFT
may require the use of hemodynamic monitoring equip-
ment, such as minimally invasive cardiac output monitor-
ing, beyond that used for simple, routine surgery. The cost
of monitoring equipment for GDFT may be a barrier to
adoption.
By reducing complication rates, GDFT would be ex-
pected to decrease cost [11]. Indeed, a favorable financial
impact of GDFT resulting from reduction of complication
rates has been reported [12,13]. These studies, however,
are not current, and involved the use of the pulmonary ar-
tery catheter for monitoring. With the exception of cardiacal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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catheter is no longer commonly used for perioperative
hemodynamic optimization, having been replaced by less
invasive technologies. To date there have been no reports
of large, randomized, controlled trials assessing the finan-
cial impact of GDFT.
The University HealthSystem Consortium (UHC) is an
alliance of 120 academic medical centers and 300 of
their affiliated hospitals [14]. Query of their database
allows the determination of complications and costs of
care in surgical patients. These data, in conjunction with
the outcome impact of GDFT that has been reported in
the medical literature, allows an estimation of potential
GDFT-related cost-savings in major surgery in the UHC.
The goal of our study was twofold: to describe the clin-
ical and economic burden of postsurgical complications
in the UHC, and to predict the economic impact of
GDFT implementation.
Materials and methods
De-identified data from all adults who had major non-
cardiac surgery in 2011 were screened in the UHC data-
base. Permission to perform and report the results of
this study was provided by the University of California
San Diego Human Research Protections Program. This
committee waived the need for informed consent, since
this was a database study.
Patient selection
Ten major surgical procedures were selected based on
previous studies showing GDFT-associated positive out-
comes [15-29]. Corresponding ICD9 codes were used to
search specific procedures in the UHC database (Table 1).
Because GDFT has thus far been shown to be effectiveTable 1 Ten major surgical procedures queried in the UHC da
morbidity reduction with GDFT
Surgical procedure ICD9 codes
Abdominal aortic aneurysm open repair 38.44
Aorto-iliac and peripheral bypass 39.25, 39.29
Esophagectomy 42.40, 42.41, 42.42
Gastrectomy 43.5, 43.6, 43.7, 43.81, 43.89, 43
Colectomy 45.71-45.76, 45.79, 45.81-4
Resection of rectum 48.40, 48.43, 48.49-48-52, 48.59, 48.6
Hepatectomy 50.22, 50.3
Pancreatectomy 52.51-52.53, 52.59, 52.6,
Total cystectomy 57.71, 57.79
Femur & hip fracture repair 79.15, 79.25, 79.35, 79.85,
UHC, University HealthSystem Consortium; GDFT, goal directed fluid therapy.only in adults, a restriction was used ensuring that only
adult (≥18 years old) patients were queried.
Clinical data collection
In-hospital postoperative complications queried, as defined
by the UHC, included postoperative stroke, gastrointestinal
hemorrhage, catheter-associated urinary tract infection,
reopening of surgical site, acute myocardial infarction,
coma or stupor, nosocomial pneumonia, wound infection,
sepsis, pulmonary embolism or deep venous thrombosis,
respiratory failure, hematoma and wound dehiscence. Mor-
bidity rate was defined as the proportion of patients devel-
oping at least one complication during their hospital stay.
Patients were sorted into two groups: those with compli-
cations and those without. For each group, in-hospital
mortality and hospital length of stay (mean ± SD) were
extracted from the UHC database and compared.
Cost data collection and cost-savings projection
Direct costs (mean ± SD) related to the in-hospital treat-
ment of patients with and without complications were ob-
tained from the UHC database and compared. Direct costs
are those associated with the actual procedures, they do
not include overheads and wages for healthcare personnel.
The most recent GDFT meta-analysis was used to estimate
the potential reduction of postoperative morbidity from
GDFT [5]. This meta-analysis reported an average odds ra-
tio of 0.77 with a confidence interval ranging from 0.71 to
0.83. Potential cost-savings were determined by using the
projected number of patients developing one or more
complication and the estimated related costs. This analysis
was performed for the entire cohort, as well as for each
surgical procedure. The analysis assumes complete, new
implementation of GDFT.tabase, corresponding ICD9 codes, and studies showing
Author (reference)
Benes [15], Kuper [19], Lobo [20], Pearse [22], Wilson [29]
Bisgaard [16], Kuper [19], Pearse [22], Wilson [29]
Boyd [17], Kuper [19], Lobo [20], Pearse [22], Wilson [29]
.91, 43.99 Boyd [17], Kuper [19], Lobo [20], Pearse [22], Wilson [29]
5.83 Benes [15], Gan [18], Kuper [19], Noblett [21], Pearse [22],
Ramsingh [24], Wakeling [28]
1-48.65, 48.69 Benes [15], Gan [18], Kuper [19], Noblett [21], Pearse [22],
Ramsingh [24], Wakeling [28], Wilson [29]
Pearse [22], Ueno [26],
52.7 Benes [15], Lobo [20], Ramsingh [24]
Boyd [17], Gan [18], Kuper [19], Pearse [22], Pillai [23],
Ramsingh [24], Wilson [29]
79.95 Kuper [19], Sinclair [25], Venn [27]
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In-hospital mortality, hospital length of stay and costs
were compared between patients with and without com-
plications. Mortality rates (%) were compared with the
chi-square test, hospital length of stay (mean ± SD) and
costs (mean ± SD) were compared with the two-sample
t-test with unequal variance.
Results
A total of 75,140 patients from 222 medical centers met
the search criteria. Numbers of patients per surgery
group are reported in Table 2. 8,421 patients developed
one or more of the 13 postsurgical complications ex-
tracted from the database (morbidity rate 11.2%). The
most common postsurgical complication was wound in-
fection (4.0%), followed by sepsis (1.8%), nosocomial
pneumonia (1.7%), reopening of surgical site (1.6%), pul-
monary embolism or deep venous thrombosis (1.5%),
and respiratory failure (1.4%). All other complication rates
were less than 1% (Figure 1). Morbidity rates for each sur-
gery group are presented in Table 2.
Clinical impact of postsurgical complications
In patients with one or more complications and in pa-
tients without any complication in-hospital mortality
was 12.4% and 1.4% (difference 11.0%, P <0.001), and mean
hospital length of stay was 20.5 ± 20.1 and 8.1 ± 7.1 days
(difference 12.4 days, P <0.001), respectively. The impact of
postsurgical complications on in-hospital mortality and
hospital length of stay for each surgery group is presented
in Table 2.
Economic impact of postsurgical complications
Average direct cost was $47,284 ± 49,170 and $17,408 ±
15,612 (difference $29,876, P <0.001) per patient withTable 2 Clinical and economic characteristics of the study po
Surgery Patients, n Morbidity, % Mortality, %
With Witho
AAA open repair 2,040 19.6 20.8 6.0
Vascular bypass 6,765 9.5 10.3 1.1
Esophagectomy 1,794 12.5 6.3 2.4
Gastrectomy 5,995 8.7 11.7 1.0
Colectomy 19,055 16.0 15.2 2.6
Resection of rectum 4,251 9.2 4.9 0.4
Hepatectomy 4,934 7.6 14.8 0.7
Pancreatectomy 6,564 14.6 11.4 0.4
Cystectomy 4,036 10.9 5.2 0.4
F&H fracture repair 19,706 7.3 10.6 0.9
In-hospital mortality, hospital length of stay (HLOS) and direct costs were compared
without any complication (Without). All comparisons were statistically significant wione or more complications and per patient with no
complications, respectively. Thus, in 2011 the UHC
spent a total of $252 M ($29,876 × 8,421 patients) to
treat postsurgical complications in the study population.
The economic impact of postsurgical complications for
each surgery group is presented in Table 2.
Projected cost-savings with implementation of GDFT
The projected number of patients developing one or
more complication, assuming an odds ratio ranging be-
tween 0.71 and 0.83, was 5,979 to 6,989 (morbidity rate
8.0 to 9.3%, Figure 2). Thus, after implementation of
GDFT, projected gross savings would be $569 to $970
per patient and $43 to 73 M for the entire UHC study
population (Figure 2). Projected cost savings for each
surgery group are presented in Figures 3 and 4.
Discussion
In our large UHC patient population, the occurrence of
one or more postsurgical complications had a dramatic
impact on in-hospital mortality (multiplied by 9.0) and
hospital length of stay (multiplied by 2.5). Although im-
pressive, these findings are consistent with the results
of a recent study [30] done in 34,256 surgical patients
discharged from a nonprofit 12-hospital system in the
southern US. In that study, in-hospital mortality was 21-
fold greater (12.3 versus 0.6%) and hospital length of stay
was 4.7-fold greater in patients who developed one or
more postsurgical complications.
Postsurgical complications also had a very significant
impact on costs (+172%), the extra costs for treating pa-
tients developing one or more complications exceeding
by far the cost of the surgical procedure itself ($29,876
versus $17,408). Our cost findings are consistent with
previous and smaller studies. In 1,200 patients undergoingpulation
HLOS, days Direct cost, $
(mean ± SD) (mean ± SD)
ut With Without With Without
23.9 ± 17.2 10.3 ± 8.2 76,169 ± 55,530 30,451 ± 24,023
17.5 ± 15.2 7.3 ± 6.5 42,202 ± 39,618 16,790 ± 12,601
23.2 ± 15.5 13.1 ± 11.7 59,382 ± 48,850 32,457 ± 30,571
25.0 ± 21.9 6.8 ± 7.7 54,879 ± 45,868 16,159 ± 15,986
23.1 ± 25.2 9.6 ± 8.2 49,160 ± 56,975 17,158 ± 16,481
16.2 ± 13.0 7.1 ± 5.3 29,874 ± 27,882 13,723 ± 10,020
17.9 ± 16.6 6.3 ± 4.4 48,961 ± 50,382 16,501 ± 12,080
21.7 ± 19.1 9.7 ± 6.9 53,217 ± 50,882 20,888 ± 15,390
19.3 ± 13.0 9.1 ± 5.4 43,598 ± 34,224 20,669 ± 10,511
14.6 ± 12.2 6.6 ± 5.9 33,890 ± 33,115 14,919 ± 13,575
between patients with one or more complications (With) and patients
th a P-value <0.001. AAA, abdominal aortic aneurysm; F&H, femur and hip.
nFigure 1 Type (x axis) and number (y axis) of postoperative complications queried in the study population (75,140 patients). P, pneumonia;
SS, surgical site; PE, pulmonary embolism; DVT, deep venous thrombosis; MI, myocardial infarction; GI, gastro-intestinal; UTI, catheter-associated urinary
tract infection.
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that patients with an uneventful course had mean costs
per case of $27,946, whereas patients with one or more
complications had a mean cost per case $34,446 higher.
In 2,250 patients undergoing general and vascular sur-
gery, Boltz et al. [32] showed that for patients developing
one, two, and three or more complications the excess
costs were $6,358, $12,802 and $42,790, respectively. In
the above mentioned 34,256-patient cohort study [30],
including major and minor procedures (for example,
appendectomy), the average cost difference between a% $M
Figure 2 Actual and projected morbidity rates, complication costs and tpatient with and without complications was $22,398.
These findings demonstrate the dramatic impact of
complications on hospital costs and highlight a rele-
vant savings capacity for major surgical procedures.
In our study, potential cost savings related to the use
of GDFT were substantial, with projected gross savings
of $569 to $970 per patient treated. This analysis re-
vealed that potential savings per patient depend on the
surgical procedure, ranging from $235 to $402 for femur
and hip fracture to $1,523 to $2,599 for abdominal aortic








otal hospital costs with goal-directed fluid therapy implementation.
$Figure 3 Projected cost-savings per patient with perioperative goal-directed fluid therapy. Each vertical black bar represents the range
between minimum and maximum savings. AAA, abdominal aortic aneurysm.
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cant ($16.6 M to 28.3 M) for colectomy (Figure 4). Our
cost-saving estimations are lower than those reported by
a previous UK prospective trial [13] showing a cost re-
duction of £1259 ($1889) per patient, and much lower
than another trial [12] reporting £3467 ($5201) cost-
savings per patient when GDFT was used. As far as we
know, these are the only two prospective studies thus far$M
Figure 4 Projected total cost-savings for the University HospitalSyste
fluid therapy. Each vertical black bar represents the range between minimcomparing the cost for treating surgical patients with
and without GDFT. These single-center evaluations
have been done in a limited number of patients moni-
tored with a pulmonary artery catheter 14 and 20 years
ago in UK hospitals. Anesthesia and surgical practices, as
well as healthcare costs, have dramatically changed over
the last decades, rendering their applicability to current
practices in the US questionable. We provide in this articlem Consortium study population with perioperative goal directed
um and maximum savings.
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meta-analysis and a very large number of patients. This is
the first clinical and economic prediction of its kind based
on real US data. Our estimations are also lower than a re-
cent cost simulation done in Sweden and suggesting that
€1882/patient ($2258) could be saved if GDFT was to be-
come the new standard of care in elderly patients with hip
fracture [33].
Although free solutions have been proposed for GDFT
[34], cardiac output monitoring techniques such as
transesophageal Doppler and arterial-pulse contour
methods are often used [35]. The cost of these tech-
nologies varies a lot from one region to the other
(depending on reimbursement policies) and from one
hospital to the other (depending on the volume of
products used or bought every year by hospitals or
group purchasers, respectively). If one assumes the cost
of GDFT technologies, including capital investment for
hemodynamic monitors and disposable sensors, to be ap-
proximately $300/patient in the US, the net savings are
projected to be $269 to $670 per treated patient. When
considering the implementation of GDFT, potential add-
itional costs related to staff training and change in fluid
or/and drug usage may also be considered. Training and
technical support are usually provided (at least in part)
by cardiac output monitoring companies, the use of vaso-
active and inotropic drugs is not part of most recent
GDFT guidelines [6-8], and recent clinical studies have
shown that the net effect of GDFT strategies is usually no
change [5] if not a decrease [36] in the total amount of
fluid administered to patients during the perioperative
period. However, GDFT costs may significantly vary from
one medical center to the other, depending on the
hemodynamic parameter used for GDFT (pulse pressure
variation versus stroke volume), the cardiac output moni-
tor amortization (large volume versus low volume of
surgery), and the fluid used (albumin versus crystalloid).
Therefore, another way to look at our data is to consider
the potential savings of $569 to $970/patient as the upper
limit for all GDFT-related costs. Then, a fair evaluation of
the potential savings can be made on a case by case basis.
Our analysis probably underestimates the potential
scope of the financial benefit of GDFT for several rea-
sons. First, the analysis was strictly limited to major sur-
gery in which outcome has already conclusively been
shown to be improved by the use of GDFT. There are
other types of surgery, such as major orthopedic spine,
solid organ transplantation, and major gynecologic sur-
gery, in which this approach would likely be associated
with fewer complications [6,19]. Second, the UHC data-
base, being an administrative database, has the advan-
tage of containing reliable financial information, but also
the disadvantage of underestimating the real incidence
of postsurgical complications. In a comparison study,Steinberg et al. [37] reported a 28% morbidity rate with
the National Surgical Quality Improvement Program
(NSQIP) database (a clinical database specifically de-
signed to collect up to 21 complications) and an 11%
morbidity rate with the UHC database in the same surgi-
cal population. In the same study [37], the incidence of
wound infection was 13% and only 1% with the NSQIP
and the UHC database, respectively. Third, we used the
odds ratio reported by the most recent GDFT meta-
analysis [5] to estimate the potential reduction of post-
operative morbidity. Because quality of care has improved
over time, results of meta-analysis may be questioned be-
cause they include studies done a long time ago. A meta-
analysis published in 2011 [4] looked specifically at the
effects of GDFT over time. Interestingly, the morbidity
reduction with GDFT was observed similarly for studies
published in the 1980s, the 1990s and after 2000. The odds
ratio for studies published after 2000 was 0.38 (0.29 to
0.50). If we had used this odd ratio, the projected savings
would have been almost two times greater than those we
report in the present study. Finally, our estimation does
not take into account costs related to hospital readmis-
sions. Postsurgical complications are the main cause for
hospital readmission and it has been recently suggested
that reducing complications may be the most efficient way
to decrease readmissions and related costs [38].
Our analysis was limited to academic centers. The sav-
ings per patient may be different when the private sector
is considered, and the total potential savings to the US
healthcare system would be considerably more if the pri-
vate sector was to be included. The potential clinical
benefits and hence cost savings were derived from a
meta-analysis, which could have incorporated reporting
bias, with positive studies more likely to have been pub-
lished. We considered the same postsurgical morbidity
reduction with GDFT for all surgical procedures. Al-
though previous meta-analyses [4,5] did not find any
interaction between the type of surgery and the effect of
GDFT, this may not always be true. Also patients with
co-morbidities may benefit more from GDFT, but this is
not something we were able to study. In addition, the as-
sumption was made that there was no GDFT being used
in 2011, whereas a survey published the same year indi-
cates that approximately 5% of US anesthesiologists con-
sistently use GDFT for high-risk surgery [9]. Further,
this study assumes complete implementation of GDFT,
which may be an unrealistic goal. The study by Kuper
et al. [19] is the only real-life and large-scale GDFT
implementation experience we know. They reported an
adoption rate of 65%. Assuming a comparable adoption
rate, our projected savings would have ranged between
$370 and $631 per patient. Finally, if costs and savings
are of utmost importance for payers, profits (reimburse-
ment – cost) are even more important for hospitals [30].
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so that we were unable to project the impact of GDFT
on hospital profits. Prospective studies are definitely re-
quired to assess the impact of GDFT implementation
not only on costs but also on hospital profits since this
may become the main driver for hospital adoption.Conclusion
Our study demonstrates the dramatic impact of postsur-
gical complications on costs (+172%) in patients under-
going major surgical procedures at UHC hospitals, and
suggests significant savings if GDFT was to be imple-
mented. Projected cost-savings per patient are the highest
for open repair of abdominal aortic aneurysm. However,
taking into account the volume of surgery, the highest
total savings for the UHC are expected to come from the
implementation of GDFT in colectomy. Outside the UHC
system, cost-savings are necessarily institution-specific, de-
pending upon local case mix, morbidity rates, surgical
costs and GDFT-related costs. Individual institutions can
use our methodology, on a local level, in their decision to
pilot and implement GDFT. Finally, we believe this ana-
lysis provides the necessary data to warrant a large and
prospective study on the economic impact of GDFT.Key messages
 We assessed the costs of postsurgical complications
in 75,140 patients undergoing 10 major abdominal,
orthopedic, vascular and urologic surgical procedures
in order to predict potential savings with perioperative
goal-directed fluid therapy (GDFT)
 Postsurgical complications were responsible for a
172% increase in hospital costs (from $17,408 to
$47,284 per patient)
 Projected cost-savings with the implementation of
perioperative GDFT ranged between $569 and $970
per patient
 Highest cost-savings per patient ($1,523 to $2,599)
were expected to come from the implementation of
GDFT for open repair of abdominal aortic aneurysm.
 Given the volume of surgery, highest savings for the
entire study population ($16.6 M to 28.3 M) were
expected to come from the implementation of
GDFT in patients undergoing colectomy
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